echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 14 QFII companies are now listed in 20 A-shares, and 3 pharmaceutical companies are under the attention.

    14 QFII companies are now listed in 20 A-shares, and 3 pharmaceutical companies are under the attention.

    • Last Update: 2020-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    , "Pharmaceutical Network Industry Dynamics" Wind data show that as of August 2, 2020 disclosed the semi-annual report of listed companies, a total of 14 QFII is now 20 A-share listed companies.
    the author after combing found that in these 20 A-share listed companies, including three pharmaceutical companies, respectively, Kelita, Hengrui Medical and Menova.
    among them, Kelly, Menova has a new, Hengrui Medical has been reduced.
    Kelly Tai Kelly attracted the attention of two QFII companies, of which the number of well-known gaoying capital positions was 17.6237 million shares, accounting for 2.47% of the outstanding shares, the holding of shares remained unchanged.
    Merrill Lynch International Limited's new Kelita, the number of positions held is 8.7831 million shares, accounting for 1.23% of the outstanding shares.
    the first half of 2020, Kelleta achieved operating income of RMB486 million, down 14.54% from the previous year; operating profit and total profit were RMB13,829.3 million and RMB13,781.03 million, respectively, down 25.25% and 25.93% from the previous year;
    the company's first-half results declined, mainly affected by the special period, product-related terminal hospital outpatient and surgical volume has been significantly reduced, hospital treatment services reduced led to the company's operating sales of various products correspondingly declined.
    data show that Kelita is mainly engaged in orthopaedic implant research and development, production and sales, is the main provider of vertebral forming minimally invasive surgery products.
    Hengrui Medical Oppenheimer Fund inc. reduced its holdings of 11.1766 million shares of Hengrui Pharmaceuticals, the pharmaceutical industry leader, in the second quarter.
    new data show that Hengrui Pharmaceuticals has a market value of more than 500 billion yuan, the industry believes that if the pharmaceutical market is booming, foreign investment in this operation to release what signals, it will need to wait and see. On the evening of July 31,
    , Hengrui Pharma announced its 2020 half-year lying report, which reported operating income of RMB11,309 million in the first half of the year, up 12.79 percent year-on-year, and net profit attributable to shareholders of listed companies was RMB2.662 billion, up 10.34 percent year-on-year.
    , Monaud Morgan Stanley International Co., Ltd. xinjin Menova, the number of shares held in 1.2766 million shares, accounting for 0.87 percent of the outstanding shares. On the evening of July 30,
    , Menova released its 2020 half-yearly report showing that the company achieved operating income of 651 million yuan in the January-June period, up 16.01 percent from a year earlier, and net profit attributable to shareholders of listed companies was 107 million yuan, up 24.57 percent from a year earlier.
    Mynova's core business is intermediates and API.
    in the first half of this year, the company's core products in this sector, such as shatatin, clopidogrere, Rishuavastatin and other new Latin American, Southeast Asian and other regions of sales, South Korea, the Middle East and Europe sales also increased.
    especially the global supply of satanproduct products, while downstream customers on the crealzogre and other products increased demand, buck ingons and anti-thrombotic products price sharply increased, raising the overall gross margin of the sector.
    The first half of the year, The Combined Gross Margin of Menova was 38.39%, up 2.01 percentage points from the previous year.
    in addition, Sinowar "Xuancheng Menova 1600 tons of API phase one project" in 2019 to achieve production, and in the first half of this year, PeiJi Pri intermediate and other products to achieve commercial production, Abidol and other products to complete the technical transfer, verification batch production.
    industry believes that with the related review, consistency evaluation, volume procurement and other medical reform policies, domestic safety and environmental protection policy tightening and global drug quality standards, the pharmaceutical industry will accelerate the transformation and upgrading, the industry towards centralization, standardization of the direction of development.
    this context, companies with the advantages of research and development, scale and product will grow rapidly.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.